(Total Views: 131)
Posted On: 01/12/2023 12:34:17 PM
Post# of 21236
$CURR is looking very good for 2023. The upcoming Q4 financial report is projected to deliver continued revenue growth and improvements based on the successful marketing of the company's wellness and anti-aging product lines.
https://finance.yahoo.com/news/cure-pharmaceu...00414.html
From the Q3 results:
*Revenue in the third quarter surged 32.1% year-over-year and 58.9% sequentially from Q2 2022 to $1.8 million with further increases expected in Q4.
*Gross margins for the third quarter improved by 123 basis points to 80.0% in 2022 compared to the same period in 2021 with expectations of continuing high margin sales with our new marketing initiatives.
*SG&A expenses (excluding non-cash charges) for the third quarter decreased by $0.1 million in 2022 compared to 2021.
*Cost reductions and operating leverage helped narrow operating loss (excluding non-cash charges) by $0.6 million in 2022 versus 2021 despite enhanced marketing investment.
https://finance.yahoo.com/news/cure-pharmaceu...00414.html
From the Q3 results:
*Revenue in the third quarter surged 32.1% year-over-year and 58.9% sequentially from Q2 2022 to $1.8 million with further increases expected in Q4.
*Gross margins for the third quarter improved by 123 basis points to 80.0% in 2022 compared to the same period in 2021 with expectations of continuing high margin sales with our new marketing initiatives.
*SG&A expenses (excluding non-cash charges) for the third quarter decreased by $0.1 million in 2022 compared to 2021.
*Cost reductions and operating leverage helped narrow operating loss (excluding non-cash charges) by $0.6 million in 2022 versus 2021 despite enhanced marketing investment.
(0)
(0)
